Stock Track | CSTONE PHARMA-B Soars 5.10% Intraday on Positive CS2009 Clinical Data for ASCO Presentation

Stock Track

Apr 22

CSTONE PHARMA-B's stock price soared 5.10% during intraday trading on Wednesday, following the company's announcement of encouraging clinical updates for its lead drug candidate CS2009.

The biopharmaceutical company disclosed that updated Phase I/II results for its trispecific antibody CS2009 in non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in 2026. The data showed encouraging anti-tumor activity in first-line lung cancer patients, including those with PD-L1 negative and low expression who typically respond poorly to immunotherapy.

Additionally, the later-line lung cancer data demonstrated deep and durable responses in heavily pretreated patients, including those previously treated with immunotherapy. The company's development plan targets global registration, with Phase III multi-regional trials expected to start by year-end following US IND clearance, driving investor optimism about the drug's potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1143505699"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1143505699\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1143505699?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-22 09:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1143505699","market":"nz","top_or_hot":-1,"title":"Stock Track | CSTONE PHARMA-B Soars 5.10% Intraday on Positive CS2009 Clinical Data for ASCO Presentation","media":"Stock Track","content":"<p>CSTONE PHARMA-B's stock price soared 5.10% during intraday trading on Wednesday, following the company's announcement of encouraging clinical updates for its lead drug candidate CS2009.</p><p>The biopharmaceutical company disclosed that updated Phase I/II results for its trispecific antibody CS2009 in non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in 2026. The data showed encouraging anti-tumor activity in first-line lung cancer patients, including those with PD-L1 negative and low expression who typically respond poorly to immunotherapy.</p><p>Additionally, the later-line lung cancer data demonstrated deep and durable responses in heavily pretreated patients, including those previously treated with immunotherapy. The company's development plan targets global registration, with Phase III multi-regional trials expected to start by year-end following US IND clearance, driving investor optimism about the drug's potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | CSTONE PHARMA-B Soars 5.10% Intraday on Positive CS2009 Clinical Data for ASCO Presentation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | CSTONE PHARMA-B Soars 5.10% Intraday on Positive CS2009 Clinical Data for ASCO Presentation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-22 09:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B's stock price soared 5.10% during intraday trading on Wednesday, following the company's announcement of encouraging clinical updates for its lead drug candidate CS2009.</p><p>The biopharmaceutical company disclosed that updated Phase I/II results for its trispecific antibody CS2009 in non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in 2026. The data showed encouraging anti-tumor activity in first-line lung cancer patients, including those with PD-L1 negative and low expression who typically respond poorly to immunotherapy.</p><p>Additionally, the later-line lung cancer data demonstrated deep and durable responses in heavily pretreated patients, including those previously treated with immunotherapy. The company's development plan targets global registration, with Phase III multi-regional trials expected to start by year-end following US IND clearance, driving investor optimism about the drug's potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1143505699","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1143505699","pubTimestamp":1776821738,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"CSTONE PHARMA-B's stock price soared 5.10% during intraday trading on Wednesday, following the company's announcement of encouraging clinical updates for its lead drug candidate CS2009.The...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B"},"translate_title":"个股追踪|基石药业-B盘中大涨5.10%因ASCO演示CS2009临床数据利好","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CSTONE PHARMA-B's stock price soared 5.10% during intraday trading on Wednesday, following the company's announcement of encouraging clinical updates for its lead drug candidate CS2009.The biopharmaceutical company disclosed that updated Phase I/II results for its trispecific antibody CS2009 in non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting in 2026. The data showed encouraging anti-tumor activity in first-line lung cancer patients, including those with PD-L1 negative and low expression who typically respond poorly to immunotherapy.Additionally, the later-line lung cancer data demonstrated deep and durable responses in heavily pretreated patients, including those previously treated with immunotherapy. The company's development plan targets global registration, with Phase III multi-regional trials expected to start by year-end following US IND clearance, driving investor optimism about the drug's potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}